Dr Sally Bennett has a career spanning medicine, equity & capital markets and investment management. She brings 25 years industry experience in senior roles across the financial sector within the life science and biopharmaceutical space.
She spent 15 years in senior roles as both a public and private investor at HealthCor, a US based global healthcare and life science investment manager and most recently co-led the firms move
into private investing. As of June 30th 2022 she acted as a Consultant to HealthCor. As of November 2022 she switched to acting as a Senior Advisor via a Consulting agreement to Catalio Capital in conjunction with its acquisition of HealthCor Management.
Prior to HealthCor, she spent ten years as a senior analyst at ING Financial Markets and then at Piper Jaffray.
Dr Bennett serves as an Independent Non-Executive Director at BerGenBio, a publicly traded European biopharmaceutical company, where she Chairs the Audit Committee and is also an Advisory Board member of the P4 Precision Medicine Accelerator Programme in the UK. She also serves on the Board of a private UK Company, Mosaic Therapeutics where she represents the Sanger Institute.
She was also a member of the Board of Governors of UCLH, an NHS Foundation Trust hospital, where she served on the Research and Innovation Committee.
She is a member of the Institute of Directors (IoD) and has been awarded the CertIoD qualification. Dr Bennett received a BSc in Anatomical Sciences and a Medical Degree, awarded with Honours, both from the University of Manchester.